Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Takashi NiizekiTakayuki TokunagaYuko TakamiYoshiyuki WadaMasaru HaradaMichihiko ShibataKazuhiko NakaoRyu SasakiFumihito HiraiSatoshi ShakadoTomoharu YoshizumiShinji ItohHiroshi YatsuhashiShigemune BekkiAkio IdoSeiichi MawatariKoichi HondaRie SugimotoTakeshi SenjuHirokazu TakahashiTakuya KuwashiroTatsuji MaeshiroMakoto NakamutaYoshifusa AratakeTsutomu YamashitaYuichiro OtsukaShuichi MatsumotoTetsuro SohdaShigeo ShimoseKenta MurotaniYasuhito TanakaPublished in: Targeted oncology (2022)
ATEZO/BEVA showed superiority to LEN in terms of prognosis and conversion rate as first-line therapy. Moreover, ATEZO/BEVA had a lower rate of severe adverse events, except for bleeding, than LEN.